Rhythm Pharmaceuticals ((RYTM)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Pharmaceuticals is conducting a study titled A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Hypothalamic Obesity (HO). The study aims to evaluate the safety, tolerability, and pharmacokinetics of RM-718 in both healthy individuals with obesity and patients suffering from hypothalamic obesity. This research is significant as it could lead to new treatment options for obesity-related conditions.
The intervention being tested is RM-718, a drug designed to be administered in single or multiple ascending doses. The purpose of RM-718 is to address obesity by potentially offering a new therapeutic approach.
The study is interventional, with a randomized allocation and a parallel intervention model. It employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment assignments. The primary goal of the study is treatment-focused.
The study began on January 25, 2024, and the latest update was submitted on October 13, 2025. These dates are crucial as they mark the timeline of the study’s progress and updates, indicating that the study is actively recruiting participants.
This clinical study update could positively influence Rhythm Pharmaceuticals’ stock performance by boosting investor confidence in the company’s research capabilities. As the obesity treatment market is competitive, successful results from this study could position Rhythm Pharmaceuticals favorably against its competitors.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.